Revitalising cancer trials post-pandemic: time for reform

The COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive r...

Descripción completa

Detalles Bibliográficos
Autores principales: Morton, Cienne, Sullivan, Richard, Sarker, Debashis, Posner, John, Spicer, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035974/
https://www.ncbi.nlm.nih.gov/pubmed/36959378
http://dx.doi.org/10.1038/s41416-023-02224-y
_version_ 1784911537986600960
author Morton, Cienne
Sullivan, Richard
Sarker, Debashis
Posner, John
Spicer, James
author_facet Morton, Cienne
Sullivan, Richard
Sarker, Debashis
Posner, John
Spicer, James
author_sort Morton, Cienne
collection PubMed
description The COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive reforms to clinical cancer research, where conventionally convoluted approvals processes, inefficient trial design, procedures and data gathering could benefit from the lessons in rationalisation learned during the pandemic.
format Online
Article
Text
id pubmed-10035974
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100359742023-03-24 Revitalising cancer trials post-pandemic: time for reform Morton, Cienne Sullivan, Richard Sarker, Debashis Posner, John Spicer, James Br J Cancer Perspective The COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive reforms to clinical cancer research, where conventionally convoluted approvals processes, inefficient trial design, procedures and data gathering could benefit from the lessons in rationalisation learned during the pandemic. Nature Publishing Group UK 2023-03-23 2023-04-12 /pmc/articles/PMC10035974/ /pubmed/36959378 http://dx.doi.org/10.1038/s41416-023-02224-y Text en © Crown 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Perspective
Morton, Cienne
Sullivan, Richard
Sarker, Debashis
Posner, John
Spicer, James
Revitalising cancer trials post-pandemic: time for reform
title Revitalising cancer trials post-pandemic: time for reform
title_full Revitalising cancer trials post-pandemic: time for reform
title_fullStr Revitalising cancer trials post-pandemic: time for reform
title_full_unstemmed Revitalising cancer trials post-pandemic: time for reform
title_short Revitalising cancer trials post-pandemic: time for reform
title_sort revitalising cancer trials post-pandemic: time for reform
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035974/
https://www.ncbi.nlm.nih.gov/pubmed/36959378
http://dx.doi.org/10.1038/s41416-023-02224-y
work_keys_str_mv AT mortoncienne revitalisingcancertrialspostpandemictimeforreform
AT sullivanrichard revitalisingcancertrialspostpandemictimeforreform
AT sarkerdebashis revitalisingcancertrialspostpandemictimeforreform
AT posnerjohn revitalisingcancertrialspostpandemictimeforreform
AT spicerjames revitalisingcancertrialspostpandemictimeforreform

Ejemplares similares